New drug, new hope: larotrectinib is on the market, the latest drug information is available in one place

Larotrectinib is a targeted anti-cancer drug that belongs to the category of TRK (neuroprimitive ectodermal tumor) inhibitors. Its unique feature is that it achieves precise intervention in cancer cells by specifically inhibiting the activity of abnormal TRK proteins in cancer patients with TRK gene fusions.

The mechanism of action of larotinib is mainly focused on targeted therapy for cancer patients with TRK gene fusion. The TRK gene encodes the nerve growth factor receptor in normal cells, but in the fusion state it may lead to abnormal TRK protein, thereby promoting the growth and differentiation of cancer cells. By inhibiting the activity of this abnormal protein, larotrectinib blocks the proliferation process of cancer cells.

The use of larotrectinib requires genetic testing to determine whether the patient hasTRK gene fusion. This personalized treatment method helps to improve the pertinence of treatment, allowing drugs to act more accurately on the patient's pathological basis.

Larotinib is mainly suitable for TRK gene fusion-positive tumor patients, including children and adults. Significant results have been achieved in some types of cancer, such as childhood soft tissue sarcoma and thyroid cancer.

Clinical trial data show that larotinib has achieved good therapeutic effects on patients with TRK gene fusion positivity, including tumor shrinkage, stabilization or complete disappearance. This brings new therapeutic hope to this specific patient group.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.